XTX Topco Ltd Sells 1,744 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

XTX Topco Ltd trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,180 shares of the biopharmaceutical company’s stock after selling 1,744 shares during the period. XTX Topco Ltd’s holdings in Gilead Sciences were worth $478,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of GILD. HHM Wealth Advisors LLC lifted its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter worth $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC raised its position in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GILD shares. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Bank of America boosted their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Wells Fargo & Company increased their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, Morgan Stanley increased their target price on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the transaction, the chief financial officer now directly owns 171,223 shares in the company, valued at $17,502,415.06. This trade represents a 44.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,540,875. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $104.49 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $130.10 billion, a P/E ratio of 282.40, a PEG ratio of 0.71 and a beta of 0.32. The stock has a 50-day moving average price of $109.16 and a 200-day moving average price of $97.63. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.